These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31466437)

  • 61. Photothermally controlled drug release system with high dose loading for synergistic chemo-photothermal therapy of multidrug resistance cancer.
    Wu X; Liu J; Yang L; Wang F
    Colloids Surf B Biointerfaces; 2019 Mar; 175():239-247. PubMed ID: 30540971
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.
    Rolle F; Bincoletto V; Gazzano E; Rolando B; Lollo G; Stella B; Riganti C; Arpicco S
    Int J Pharm; 2020 Apr; 580():119191. PubMed ID: 32142738
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment.
    An D; Yu X; Jiang L; Wang R; He P; Chen N; Guo X; Li X; Feng M
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652957
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NIR-Laser-Controlled Drug Release from DOX/IR-780-Loaded Temperature-Sensitive-Liposomes for Chemo-Photothermal Synergistic Tumor Therapy.
    Yan F; Duan W; Li Y; Wu H; Zhou Y; Pan M; Liu H; Liu X; Zheng H
    Theranostics; 2016; 6(13):2337-2351. PubMed ID: 27877239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
    Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
    Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
    Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
    Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
    Ong JC; Sun F; Chan E
    J Liposome Res; 2011 Dec; 21(4):261-71. PubMed ID: 21226547
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
    Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
    Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
    Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
    Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cit/CuS@Fe
    Zhu X; Huang H; Zhang Y; Zhang H; Hou L; Zhang Z
    J Biomater Appl; 2017 Feb; 31(7):1010-1025. PubMed ID: 28178904
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NIR responsive liposomal system for rapid release of drugs in cancer therapy.
    Chen MM; Liu YY; Su GH; Song FF; Liu Y; Zhang QQ
    Int J Nanomedicine; 2017; 12():4225-4239. PubMed ID: 28652729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.